Current Report Filing (8-k)
October 13 2020 - 04:28PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act
of 1934
Date of Report (date of earliest event reported): October 13,
2020
iBio, Inc.
(Exact name of registrant as specified in charter)
Delaware
(State or other jurisdiction of incorporation)
001-35023 |
26-2797813 |
(Commission
File Number) |
(IRS
Employer Identification No.) |
8800 HSC Parkway
Bryan, Texas 77807
(Address of principal executive offices and zip code)
(979) 446-0027
(Registrant’s telephone number including area code)
N/A
(Former Name and Former Address)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of registrant under
any of the following provisions:
|
¨ |
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425) |
|
¨ |
Soliciting
material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR
240.14a-12) |
|
¨ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b)) |
|
¨ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
Title
of each class |
Trading
Symbol(s) |
Name
of each exchange on which registered |
Common
Stock, $0.001 par value per share |
IBIO |
NYSE
American |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
|
|
Emerging
growth company ¨ |
|
If an
emerging growth company, indicate by checkmark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act.
¨
Item 2.02. Results of Operations and Financial
Condition.
On October 13, 2020, iBio, Inc. (the “Company”) issued a press
release announcing its financial results for the fiscal year ended
June 30, 2020. A copy of the press release is furnished as Exhibit
99.1 to this Current Report on Form 8-K and is incorporated herein
by reference.
The information in this Item 2.02 and in the press release
attached as Exhibit 99.1 to this Current Report on Form 8-K shall
not be deemed to be “filed” for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended, or otherwise subject
to the liabilities of that section or Sections 11 and 12(a)(2) of
the Securities Act of 1933, as amended. The information contained
in this Item 2.02 and in the press release attached as Exhibit
99.1 to this Current Report on Form 8-K shall not be incorporated
by reference into any filing with the U.S. Securities and Exchange
Commission made by the Company, whether made before or after the
date hereof, regardless of any general incorporation language in
such filing.
Item 9.01. Financial Statements and
Exhibits.
(d) Exhibits.
The following exhibit is furnished with this Current Report on Form
8-K.
Signatures
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
IBIO INC. |
|
|
Date:
October 13, 2020 |
By: |
/s/
Thomas F. Isett |
|
|
|
Name: |
Thomas
F. Isett |
|
|
|
Title: |
Chairman
and Chief Executive Officer |
|
|
|
|
|
iBio (AMEX:IBIO)
Historical Stock Chart
From Dec 2020 to Jan 2021
iBio (AMEX:IBIO)
Historical Stock Chart
From Jan 2020 to Jan 2021